| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 25.06. | Merck KGaA to buy Bio-Techne for $11.3bn in life science footprint expansion | ||
| 25.06. | MSD's Keytruda-Padcev combo secures EC approval for MIBC | ||
| 25.06. | RQ Bio secures $115m to develop influenza antibody programme | ||
| 25.06. | BIO 2026: How NIH cuts have threatened US competitiveness against China | ||
| 24.06. | Novartis targets undruggable cancers with $1.9bn Antares Therapeutics deal | ||
| 24.06. | OURA and Lilly join forces to harmonise drug-wearable obesity care | ||
| 24.06. | Boehringer and Combotope partner for cancer antibodies | ||
| 24.06. | Haisco and Nuvectis sign licensing deal for two drugs | ||
| 23.06. | BIO 2026: NVIDIA announces the BioNeMo toolkit for AI agents | ||
| 23.06. | FDA changes rare disease tune again as it clears path for Regenxbio's gene therapy | ||
| 23.06. | Genprex's Reqorsa combo secures Canadian patent for lung cancer | ||
| 23.06. | BIO 2026: Drug manufacturers band together to tackle employment challenges | ||
| 23.06. | Lilly and BioArctic sign deal to develop neurodegenerative therapy | ||
| 22.06. | AbbVie deepens immunology legacy in $10.9bn Apogee buyout | ||
| 22.06. | HLTH Europe 2026: enriching the patient journey with health technologies | ||
| 22.06. | Moderna's mRNA flu vaccine passes FDA AdCom, review underway | ||
| 22.06. | Moderna's mRNA flu vaccine set for FDA review after positive AdCom | ||
| 22.06. | Sun Pharma to acquire Innovcare Lifesciences for $28.7m | ||
| 22.06. | Japan approves Sanofi's Sarclisa combo for MM treatment | ||
| 19.06. | Biopharma industry confidence at highest in years despite geopolitical headwinds | ||
| 19.06. | Voro and Alloy partner on tumour-selective TCE therapeutics | ||
| 19.06. | Biogen to acquire RayThera for up to $1bn | ||
| 18.06. | UniQure to seek approval of Huntington's gene therapy after FDA U-turn | ||
| 18.06. | Jazz and AbCellera sign deal for T-cell engagers in solid tumours | ||
| 18.06. | LG AI Research and D&D Pharmatech sign agreement for oral peptide drugs |